Despite a 10-fold increase of T cell dose, the incidence and severity of acute GVHD following allogeneic transplantation of G-CSF-mobilized PBSC is not increased compared to BMT. Experimental murine studies demonstrate that G-CSF polarizes donor T cells toward a type 2 cytokine response. 
reduction of acute GVHD may be attributed to immunomodulatory effects of G-CSF on donor T cells. In experimental murine models of allogeneic PBSCT, G-CSF treatment in donors has been found to polarize donor T cells towards a type 2 cytokine response with increased IL-4 production and decreased IL-2 and IFN-␥ production, corresponding to a reduction in acute GVHD. [9] [10] [11] Polarized type 2 alloreactive donor T cells have been shown to protect mice from acute GVHD. 12 However, type 2 polarization by G-CSF has yet to be demonstrated in humans. Instead, studies of G-CSF-mobilized blood in humans have demonstrated a reduced T cell proliferative response of PBMC in MLR after G-CSF administration. [13] [14] [15] [16] [17] [18] [19] [20] This suppression has been attributed to large amounts of monocytes in G-CSF-mobilized PBSC. 15, 16, 20, 21 In order to address these issues, we studied proliferative and cytokine responses to alloantigens and Con A of nonadherent PBMC (NAC) and CD3 ϩ T cells positively selected from NAC obtained from normal individuals before and after G-CSF administration.
Materials and methods

G-CSF administration
Seven donors for allogeneic PBSCT and four normal volunteers entered into the study after giving informed consent to this protocol, which was approved by the Institutional Review Board of Okayama University Hospital. Ages of donors and volunteers ranged from 20 to 42 years. Seven were male and two were female. Each individual was treated subcutaneously with recombinant human G-CSF (Kirin-Sankyo, Tokyo, Japan; Chugai Pharmaceuticals, Tokyo, Japan; and Kyowa Pharmaceuticals, Tokyo, Japan) at a dose of 10 g/kg once daily for 4 or 5 days.
Cells
Heparinized peripheral blood samples were obtained by venous puncture or leukapheresis (LP) before and after G-CSF administration. LP was performed using a Cobe Spectra Cell Separator (COBE Laboratories, Lakewood, CO, USA) as described previously. 22 The LP products were centrifuged at 200 g for 5 min to remove platelets. PBMC were isolated from the heparinized blood or the LP products by Histopaque (1.077 g/ml, Sigma, St Louis, MO, USA) density gradient centrifugation, washed twice in phosphatebuffered saline (PBS) and resuspended in RPMI 1640 sup-plemented with 10% pooled, heat-inactivated human AB serum, 100 U/ml penicillin and 100 g/ml streptomycin (complete medium). PBMC were then incubated in a plastic dish at a concentration of 2 ϫ 10 6 cells/ml at 37°C for 60 min to remove plastic-adherent cells. Nonadherent PBMC obtained before and after G-CSF administration were referred to as preG-NAC and G-NAC, respectively. Remaining adherent cells were incubated in PBS supplemented with 0.5% ethylenediaminetetraacetic acid (EDTA) and fetal calf serum (FCS) for 30 min at 4°C during which time they detached from the T-75 flask (Coaster, Cambridge, MA, USA) surface. The supernatant containing adherent cells was then harvested, washed three times with RPMI 1640 containing 10% FCS, and resuspended in complete medium. CD3 ϩ cells were positively isolated using Dynabeads M-450 CD3 MoAb (Dynal, Oslo, Norway) according to the manufacturer's protocols. Briefly, cells were stained with CD3 beads at a 1:4 ratio and incubated for 30 min at 4°C on an apparatus that provides both gentle tilting and rotation. After incubation, rosetted cells positively selected using a magnet were incubated overnight in complete medium at 37°C in 5% CO 2 in T-75 flasks to remove the beads from cells. CD3 ϩ cells were then collected after removing M-450 CD3 beads with a magnet. According to the manufacturer's protocol, CD3 antigen expression, which is transiently downregulated during these procedures, is recovered on the cell surface after 24 h of culture.
In some experiments CD4 ϩ cells were also positively selected after primary MLR by using Mini-MACS (Miltenyi Biotec, Sunnyvale, CA, USA) according to the manufacturer's protocol. Briefly, cells were incubated with mouse IgG 1 anti-human CD4 MoAb at 4°C for 30 min. CD4 ϩ cells were then separated by positive selection using a magnetic column and separator. Cells were resuspended in complete medium for further experiments. Purity of the CD3 ϩ cells and CD4 ϩ cells was always more than 90% and the viability of these cells exceeded 95% as determined by trypan blue exclusion.
Flow cytometric analysis
Surface marker analyses were performed by one-or twocolor flow cytometry using a FACS Calliber (Becton Dickinson, San Jose, CA, USA). All MoAb were purchased from Becton Dickinson. Cells were stained with MoAb conjugated with PE directed to CD8 and CD14, or with MoAb conjugated with FITC directed to CD3 and CD4. Conjugated isotype-matched antibodies were used for control staining. Sample suspensions were adjusted to 10 6 cells/ml and incubated on ice with the appropriate antibody for 20 min, washed twice, and were resuspended in 0.5 ml 1% bovine serum albumin (BSA) in PBS. Dead cells were excluded by electronic gating and 30 000 gating events were analyzed for each sample. ϩ cells isolated from MNC after primary MLR were used as effector cells of the secondary MLR. Cell proliferation was determined as described above.
Analysis of cell proliferation
ELISA
To determine cytokine production, responder cells (1 ϫ 10 6 cells) were cocultured with irradiated, allogeneic stimulator cells (1 ϫ 10 6 cells) or with 10 g/ml of Con A in 1 ml of complete medium in 24-well, flat-bottomed plates (Costar) at 37°C in 5% CO 2 in duplicate. Cell-free supernatants were harvested after 48 h of culture and were stored at Ϫ80°C until use. ELISA kits (Human high sensitivity IL-4 ELISA kit, Human IFN-␥ ELISA kit; R&D Systems, Minneapolis, MN, USA) were used to measure cytokine levels according to the manufacturer's protocols. Each supernatant was measured in duplicate by a microplate reader (Bio-Rad Labs, Hercules, CA, USA). Minimal detectable levels of IL-4 and IFN-␥ were 0.090 pg/ml and 15.6 pg/ml, respectively.
Statistical analysis
Data represent mean Ϯ standard error (s.e.). The statistical significance was analyzed by Student's paired t-test. Differences with a P value less than 0.05 were considered significant.
Results
T cell proliferative responses to allogeneic stimulation and Con A were impaired in G-CSF-mobilized PBSC
We removed adherent cells from PBMC by plastic adherence, since the frequency of T cells in post-G-CSF PBMC was lower than that before G-CSF administration (41% vs 63%) due to contamination by a large number of monocytes (18% vs 38%), as has been reported. [15] [16] [17] Following plastic adherence, the frequency of T cells and monocytes was determined by FACS analysis in preG-NAC and G-NAC obtained from each individual. Depletion of adherent cells resulted in a decrease in the percentage of monocytes and an increase in the percentage of T cells. In preG-NAC, the percentages of CD3 ϩ , CD4 ϩ , CD8 ϩ and CD14 ϩ cells were 77 Ϯ 3, 38 Ϯ 4, 32 Ϯ 5 and 9 Ϯ 3%, respectively. Those in G-NAC were 73 Ϯ 5, 39 Ϯ 3, 28 Ϯ 5 and 16 Ϯ 6%, respectively. The frequency of each population was not significantly different between preG-NAC and G-NAC. The CD4 to CD8 ratio was also equivalent in the two populations. When cells were cultured with allogeneic stimulators for 7 days, T cell proliferation was reduced in G-NAC compared to that in preG-NAC (845 Ϯ 342 c.p.m. vs 4119 Ϯ 1814 c.p.m.), despite the equivalent cell compositions (Table 1) . T cell proliferation in G-NAC was also significantly reduced compared to that in preG-NAC when percentages of control (preG-NAC) were used to summarize the differences (55 Ϯ 21% of preG-NAC, P Ͻ 0.01). A similar hypoproliferative response was observed in G-NAC upon stimulation with Con A (654 Ϯ 471 c.p.m. vs 1217 Ϯ 468 c.p.m.) (58 Ϯ 9% of control, P Ͻ 0.01).
T cell hypoproliferative response in G-NAC was associated with decreased production of both IFN-␥ and IL-4
In order to investigate whether a reduced T cell alloresponse in G-NAC is associated with polarization of T cells towards a type 2 cytokine profile, as has been observed in murine studies, [9] [10] [11] IFN-␥ and IL-4 levels in the culture supernatant were measured. The kinetics of IFN-␥ and IL-4 production in G-NAC induced by either allogeneic stimulation or Con A stimulation were similar to those of preG-NAC. Our preliminary kinetic study of the production of IFN-␥ and IL-4 demonstrated the level of these cytokines reached the maximum at 48 h of culture (data not shown). Production of cytokines in response to allogeneic stimulation was reduced in G-NAC compared to that in preG-NAC (IFN-␥: 157 Ϯ 81 pg/ml vs 321 Ϯ 51 pg/ml, IL-4: 0.62 Ϯ 0.26 pg/ml vs 3.5 Ϯ 2.2 pg/ml). These differences were statistically significant when percentages of control (preG-NAC) were used to summarize the differences (IFN-␥: 49 Ϯ 21%, P Ͻ 0.05, IL-4: 55 Ϯ 14%, P Ͻ 0.05) ( Table 1) . Con A-induced production of IFN-␥ and IL-4 was also reduced in G-NAC. Table 1 Proliferative and cytokine responses of preG-NAC and G-NAC to alloantigen and Con A 1 ϫ 10 5 preG-NAC and G-NAC were cultured with 1 ϫ 10 5 irradiated allogeneic PBMC in triplicate for 7 days or with 10 g/ml of Con A for 3 days and were pulsed with 0.25 Ci of 3 H-thymidine for the last 18 h (n ϭ 7). For determination of cytokine production, 1 ϫ 10 6 preG-NAC and G-NAC were cultured with irradiated allogeneic PBMC or 10 g/ml of Con A in triplicate (n ϭ 6). The supernatants were collected at 48 h. Data represent mean Ϯ s.e. *P Ͻ 0.05; **P Ͻ 0.01.
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Proliferative and cytokine responses were restored in CD3 ϩ T cells positively selected from G-NAC
We then tested alloresponses of CD3 ϩ cells positively selected from preG-NAC and G-NAC. Although positive selection using anti-CD3 mAb can stimulate T cells via the CD3/TCR complex, these cells did not proliferate or produce cytokines in a 7-day culture without further stimulation. Interestingly, proliferative and cytokine responses to allogeneic stimulation in purified CD3 ϩ cells from G-NAC were equivalent to those from preG-NAC (Table 2) .
T cell alloreactivity in MLR in the presence of post-G-CSF monocytes was less than that in the presence of pre-G-CSF monocytes
Based on the results of these experiments, we hypothesized that monocytes after G-CSF administration are responsible for the inhibition of T cell responses. We therefore performed add-back studies of monocytes to test suppressive function of post-G-CSF monocytes in MLR. Adherent cells were isolated from PBMC obtained before and after G-CSF administration. Viability of these purified monocytes always exceeded 95% as determined by trypan blue dye exclusion, and purity of monocytes always exceeded 90% as determined by CD14 positivity on flow cytometry. The frequency of CD14 ϩ monocytes determined by FACS analysis was not different between pre-G-CSF monocytes and post-G-CSF monocytes. 1 ϫ 10 5 of PBMC obtained prior to G-CSF administration were cultured with 1 ϫ 10 5 irradiated third party PBMC for 7 days in the presence of autologous monocytes obtained before or after G-CSF administration. T cell proliferation in MLR was less when post-G-CSF monocytes were added to the cultures than when cultured in the presence of pre-G-CSF monocytes (Figure 1 ).
G-CSF did not affect MLR activity in vitro
Experiments were conducted to determine whether G-CSF directly modulates monocyte function in vitro. PBMC obtained from normal individuals were cultured for 7 days with irradiated third party allogeneic stimulators in the presence or absence of G-CSF. MNC recovered from primary culture or CD4 ϩ cells isolated from these MNC were restimulated with alloantigen and T cell proliferation was Table 2 Proliferative and cytokine response of CD3 ϩ cells isolated from preG-NAC and G-NAC to alloantigen 18 h (n ϭ 7) . For determination of cytokine production, 1 ϫ 10 6 CD3 ϩ cells were cultured with irradiated allogeneic PBMC in triplicate (n ϭ 5). The supernatants were collected at 48 h. Data represent the mean Ϯ s.e. measured 48 h later. As shown in Table 3 , secondary MLR activity of MNC and CD4 ϩ cells was not affected by the addition of G-CSF to the primary culture, suggesting that the mechanism of G-CSF-induced modulation of monocyte function is indirect.
Discussion
Potential mechanisms for the lack of increase in the incidence and severity of acute GVHD in allogeneic PBSCT Table 3 In vitro effect of G-CSF on T cell proliferation in secondary MLR compared to BMT, despite the marked increase in T cell numbers in PBSC grafts, have been widely investigated.
The majority of studies in humans has focused on reduced T cell alloreactivity in post-G-CSF PBMC in MLR. [13] [14] [15] [16] [17] [18] [19] [20] However, the hyporesponsiveness of PBMC in MLR does not allow for precise conclusions about donor T cells, since the cell composition of post-G-CSF PBMC is notably different from steady-state PBMC due to contamination by a higher number of monocytes in post-G-CSF PBMC. [15] [16] [17] Therefore, adherent cells were roughly depleted from PBMC by plastic adherence in this study in an attempt to normalize T cell numbers. As a consequence of adherent cell depletion, frequencies of T cells and monocytes were similar in G-NAC and preG-NAC, although there were still about 10% CD14 ϩ monocytes in NAC. Nonetheless, proliferative responses of G-NAC to alloantigen and Con A were significantly less than those of preG-NAC. This observation confirms previous studies demonstrating decreased responses of post-G-CSF PBMC to allogeneic stimulation and mitogens, [13] [14] [15] [16] [17] [18] [19] [20] even when T cell and monocyte numbers were normalized.
Although murine models of PBSCT suggested that G-CSF treatment of the donor shifted the cytokine profile to favor a type 2 pattern in both donors and recipients after allogeneic PBSCT, 9-11 the cytokine profile of donor T cells following high-dose G-CSF administration has not been fully investigated in humans. Our studies demonstrated reduced production of a type 2 cytokine, IL-4, as well as a type 1 cytokine, IFN-␥, in G-NAC in association with a reduced T cell proliferative response. A previous study in humans demonstrated that levels of type 1 cytokines (IL-2 and IFN-␥) in the supernatant of an MLR were reduced when irradiated post-G-CSF PBMC were used as the stimulator. 17 It suggests the reduced ability of post-G-CSF PBMC to stimulate allogeneic T cells.
Interestingly, T cell responses to allogeneic stimulation were completely restored in CD3 ϩ T cells positively selected from G-NAC; proliferation and production of IFN-␥ and IL-4 in CD3 ϩ T cells were similar before and after G-CSF treatment. This confirms our preliminary study demonstrating normal proliferative responses of post-G-CSF CD4 ϩ or CD8 ϩ cells to those of pre-G-CSF corresponding cells, 18 and a previous study demonstrating the restoration of T cell proliferative response to CD3 stimulation by the removal of CD14 ϩ monocytes. 20 It has also been shown that T cells in GM-CSF-mobilized PBSC have a depressed mitogenic response to PHA, but positively selected CD4 ϩ and CD8
ϩ T cells from PBSC showed normal mitogenic response. 23 Collectively, these results suggest the lack of an intrinsic defect of T cells and the presence of suppressive effects of accessory cells in apheresis products, although we cannot rule out the possibility that positive selection procedures will restore T cell function.
We demonstrated that IFN-␥ and IL-4 production was suppressed in G-NAC but normal in post-G-CSF CD3 ϩ T cells. Therefore, polarization of donor T cells toward type 2 cytokine response by G-CSF treatment is not likely in humans as it is in mice. A couple of studies of the cytokine profile in humans using a reverse transcriptase-polymerase chain reaction (RT-PCR)-based method suggested that G-CSF-mobilized PBMC tend to constitutively express more type 2 cytokines in both donors and recipients of allogeneic PBSCT. 24, 25 Recently, it was reported that G-CSF-mobilized PBSC obtained from cancer patients constitutively express significantly higher levels of IL-2, 4 and 10, IFN-␥ and TNF-␣ as compared to normal PBMC. 26 Furthermore, mRNA expression of the cytokines IL-2, 4 and 10 and IFN-␥ in purified CD4 ϩ and CD8 ϩ cells from PBSC were higher compared with those from normal PBSC. 27 Our data, however, do not agree with the results of these studies, probably due to the differences in the experimental methods used. Prior studies detected cytokine mRNA expression on unstimulated cells with a RT-PCR technique, while our study measured cytokines in the supernatant of stimulated cells by ELISA.
Our add-back studies of autologous monocytes in MLR confirm the role of post-G-CSF monocytes in the suppression of T cell proliferative responses in vitro as previously described, 15, 16, 20, 21 although we cannot deny the possibility that other cells, such as B cells and granulocytes in PBSC products, may also be suppressive. Suppressive effects of monocytes have been attributed to IL-10 production by a large number of monocytes, 20, 27 as well as reduced expression of the costimulatory molecule CD86 on monocytes 15 and impaired induction of the CD28 responsive complex on T cells in G-PBMC, 21 which therefore provide suboptimal amounts of costimulatory signals. It was also shown that inhibition of monocytic IL-12 and TNF-␣ production by G-CSF indirectly attenuates IFN-␥ release from T cells. 28 A recent study suggests that primed Fas ϩ CD4 ϩ T cells in G-CSF-mobilized PBSC interact with activated Fas ligand ϩ monocytes, resulting in apoptosis. 29 The circulatory half-life of monocytes is approximately 3 days and monocytes can migrate into peripheral tissue where alloreactive responses take place. 30, 31 Therefore, although there is no direct evidence that infused post-G-CSF monocytes affect T cells in vivo, it is possible that infused monocytes suppress alloreactivity of T cells in vivo. A comparative study of immune reconstitution after allogeneic BMT and PBSCT demonstrated that monocyte count early after PBSCT was greater than that after BMT, but it rapidly declined to the comparable level after BMT. 6 It is tempting to speculate that the large numbers of G-CSF-mobilized monocytes contained in PBSC suppress alloresponses of T cells, leading to the relative decrease in acute GVHD, and that T cell alloresponses are restored as monocytes disappear, leading to the increase in incidence of chronic GVHD. 32 We then asked whether G-CSF modulates monocyte Bone Marrow Transplantation function directly. We did not demonstrate a direct effect of G-CSF on PBMC in secondary MLR when G-CSF was added into a 7-day primary MLR culture. This confirms our previous study demonstrating no direct effect of G-CSF in primary MLR. 18 We recently found that post-G-CSF monocytes were functionally and phenotypically different from steady-state monocytes (Sunami K et al, unpublished observation). These alterations, however, were not replicated by culturing monocytes with G-CSF in vitro. Thus, modulation of monocyte function seems to be induced by mobilization of functionally different monocytes or by complicated interactions of cells and/or humoral factors in vivo.
In summary, our results suggest that G-CSF treatment indirectly modulates monocyte function to inhibit T cell proliferative and cytokine responses to alloantigen and mitogen and that T cell functions can be restored by the depletion of these accessory cells.
